Back to results
US 2022/0177472 A1Published application
Imidazoquinoline compounds and prodrugs thereof
AssigneesUniversity of Kansas, HylaPharm, LLC
InventorsLaird Forrest, Daniel Aires, Ryan Moulder, Ruolin Lu, Jordan Hunt, Peter Kleindl, Ti Zhang, Chad Groer, Shuang Cai
Life of this patent
Estimating the term…
Abstract
The present technology is directed to TLR7 and TLR8 agonist compounds, compositions, and methods of using the same for the treatment of cancers and as vaccine adjuvants.
Claims24
A compound of Formula I
- or a pharmaceutically acceptable salt thereof, wherein
- X1 is H, halo, hydroxy, amino, cyano, trifluoromethyl, thiol, alkylthio, sulfoxide, sulfone, nitro, pentafluorosulfanyl, carboxylate, amide, ester, C1-C6 alkyl, C1-C6 alkoxy, aryl, aryloxy, C1-C6 alkanoyl, C1-C8 alkanoyloxy, aryloyl, aryloyloxy,
- X2 is H, hydroxyl,
- m is 1, 2, 3, 4, 5, 6, 7, or 8;
- n is 1, 2, or 3;
- p is 1, 2, 3, 4, 5, 6, 7, or 8;
- and
- X3 is CH2 or O;
- provided that at least one of X1 and X2 is not
- and
- wherein the compound of Formula I is not
8 more elements
(canceled)
(canceled)
-25. (canceled)
-28. (canceled)
Dependencies are inferred from the claim text.